German biotech BioNTech and U.S. drugmaker Pfizer Inc on Monday said data from an early-stage trial of their experimental coronavirus vaccine showed that it prompted an immune response and was well-tolerated, similar to results seen in prior early test.
FILE PHOTO: A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange in New York, U.S., July 29, 2019. REUTERS/Brendan McDermid
In the German study, the vaccine also generated a high level of T cell responses against the coronavirus. T cells, a type of white blood cell, are an important component of the immune system’s attack against foreign invaders, such as viruses. The results come as separate results were released for two other experimental COVID-19 vaccines on Monday.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Britain Secures 90 Million Doses Of Potential Coronavirus Vaccines From Pfizer, BioNTech & ValnevaAn effective vaccine is yet to be proven, however the U.K. has now secured access to up to 230 million vaccine doses.
続きを読む »
Britain signs deals with Pfizer, BioNTech, Valneva for COVID-19 vaccinesBritain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from the Pfizer Inc and BioNTech alliance and French group Valneva, the business ministry said on Monday.
続きを読む »
Britain Secures 90 Million Doses Of Potential Coronavirus Vaccines From Pfizer, BioNTech & ValnevaAn effective vaccine is yet to be proven, however the U.K. has now secured access to up to 230 million vaccine doses.
続きを読む »
Britain Secures 90 Million Doses Of Potential Coronavirus Vaccines From Pfizer, BioNTech & ValnevaAn effective vaccine is yet to be proven, however the U.K. has now secured access to up to 230 million vaccine doses.
続きを読む »